Novo Nordisk raised its 2026 financial forecast after sales of its Wegovy weight-loss pill outperformed company expectations [1, 2].
The update signals a critical shift for the pharmaceutical giant as it attempts to maintain dominance in the competitive GLP-1 market. By transitioning from injections to a pill format, the company is expanding its reach to patients who prefer oral medication over needles.
In first-quarter results released on May 6, the company reported that Wegovy sales reached $2.5 billion [1]. This performance allowed Novo Nordisk to revise its full-year profit outlook, cutting the expected decline to 12% from a previous projection of 13% [1, 3].
"We are seeing strong demand for Wegovy, which is driving our performance and allowing us to raise guidance for the year," CEO Lars Fruergaard Jørgensen said [1].
The surge in revenue follows the January launch of the oral version of the drug. Sanne Wass said the launch exceeded expectations and served as a key catalyst for the quarter's results [2].
Investors responded positively to the news, with the company's share price seeing a 5.2% intraday gain [4]. The strong demand for the pill has helped the company offset a broader slowdown observed across the weight-loss drug market [1].
"Our revised outlook now reflects a 12% decline in profit for the full year, compared with the 13% decline we had previously projected," a Novo Nordisk CFO said [3].
“"We are seeing strong demand for Wegovy, which is driving our performance and allowing us to raise guidance for the year."”
The success of the oral Wegovy pill suggests that patient preference for non-injectable delivery systems is a primary driver of market growth. While the company is still forecasting a profit decline for the year, the narrowed gap indicates that the new product line is effectively cushioning the impact of market volatility and competition in the obesity treatment sector.
